Table 1 Result comparison of expected vs. projected 3-year cumulative incidence (%) outcomes for empagliflozin + SoC and comparators post CDM CV outcome calibration
Event | Empagliflozin + SoC | Sitagliptin + SoC | Liraglutide + SoC | |||
|---|---|---|---|---|---|---|
From EMPA-REG OUTCOME | Calibrated | Estimated by ITC | Calibrated | Estimated by ITC | Calibrated | |
Death from any cause | 5.82 | 5.78 | 8.69 | 8.67 | 7.28 | 7.24 |
Death from CV causes | 3.72 | 3.68 | 6.20 | 6.13 | 4.65 | 4.63 |
MI | 5.04 | 5.05 | 5.04 | 5.00 | 5.09 | 5.08 |
Angina | 3.00 | 3.01 | 3.00 | 3.01 | 3.00 | 3.06 |
Stroke | 3.69 | 3.70 | 3.69 | 3.69 | 2.72 | 2.71 |
HF | 2.82 | 2.83 | 4.34 | 4.36 | 3.76 | 3.79 |
MAU | 75.75 | 75.86 | 79.8 | 79.1 | 75.75 | 76.76 |
GRP | 12.54 | 12.34 | 19.47 | 14.89 | 12.54 | 9.17 |
ESRD | 0.3 | 0.3 | 0.63 | 0.54 | 0.3 | 0.28 |